Compare TGTX & HLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TGTX | HLI |
|---|---|---|
| Founded | 1993 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 9.6B |
| IPO Year | 2008 | 2015 |
| Metric | TGTX | HLI |
|---|---|---|
| Price | $55.16 | $138.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $49.80 | ★ $194.29 |
| AVG Volume (30 Days) | ★ 2.8M | 614.6K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.54% |
| EPS Growth | ★ 1746.67 | 6.87 |
| EPS | 0.12 | ★ 6.22 |
| Revenue | $2,785,000.00 | ★ $2,617,516,000.00 |
| Revenue This Year | $49.08 | $13.77 |
| Revenue Next Year | $26.69 | $12.10 |
| P/E Ratio | $457.67 | ★ $21.58 |
| Revenue Growth | N/A | ★ 9.55 |
| 52 Week Low | $25.37 | $131.31 |
| 52 Week High | $57.38 | $211.78 |
| Indicator | TGTX | HLI |
|---|---|---|
| Relative Strength Index (RSI) | 77.96 | 46.87 |
| Support Level | $28.57 | $134.84 |
| Resistance Level | $57.38 | $144.57 |
| Average True Range (ATR) | 2.39 | 3.92 |
| MACD | 0.24 | 0.08 |
| Stochastic Oscillator | 81.53 | 52.69 |
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.